SCHEDULE 13D/A: Samsara BioCapital Reduces Stake in Syros Pharmaceuticals Below 5% Threshold
Beneficial Ownership Amendment
Samsara BioCapital and its affiliates have significantly reduced their beneficial ownership in Syros Pharmaceuticals, Inc., falling below the 5% threshold due to recent open market sales.
Summary
- Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, and Srinivas Akkaraju (the "Reporting Persons") have filed an Amendment No. 2 to their Schedule 13D regarding their holdings in Syros Pharmaceuticals, Inc.
- The filing indicates that the Reporting Persons ceased to be beneficial owners of more than five percent of Syros Pharmaceuticals' common stock on November 20, 2024.
- As of the filing, the Reporting Persons beneficially own 707,114 shares of common stock, representing 2.6% of the Issuer's outstanding shares.
- This percentage is based on 26,832,457 shares of common stock outstanding as of October 24, 2024, as reported in Syros Pharmaceuticals' Quarterly Report on Form 10-Q filed October 31, 2024.
- The current beneficial ownership primarily consists of warrants exercisable for 707,114 shares.
- Samsara LP conducted open market sales of 958,310 shares on November 18, 2024, at an average price of $0.21 (ranging from $0.18 to $0.26).
- Samsara LP further sold 74,128 shares on November 19, 2024, at an average price of $0.21.
- On November 20, 2024, Samsara LP sold an additional 753,989 shares at an average price of $0.26 (ranging from $0.26 to $0.27).
- Dr. Akkaraju also sold 9,333 shares on December 30, 2024, at an average price of $0.25.
Sentiment
Score: 3
Explanation: The sentiment is negative as a significant investor has reduced their stake, which can be perceived as a lack of confidence in the company's future performance. However, it's a filing about an investor's actions, not the company's direct operational performance, so it's not extremely negative.
Negatives
- A significant institutional investor, Samsara BioCapital, has reduced its stake in Syros Pharmaceuticals, Inc. below the 5% beneficial ownership threshold.
- The reduction in stake was executed through multiple open market sales of common stock and warrants between November 18, 2024, and December 30, 2024.
- The sales occurred at relatively low price points, ranging from $0.18 to $0.27 per share.
Risks
- The reduction in beneficial ownership by a major investor like Samsara BioCapital could signal a lack of confidence in the company's future prospects or a shift in the investor's strategy, potentially leading to negative market perception and increased selling pressure on the stock.
Future Outlook
NA
Industry Context
This filing reflects a change in investment position by a venture capital firm in a biotechnology company. While specific industry trends are not detailed, such a reduction in stake by a significant investor can be observed across the biotech sector, particularly for companies in early development stages or facing funding challenges, as investors re-evaluate portfolios.
Stakeholder Impact
- Shareholders: The reduction in stake by a significant investor could lead to negative market sentiment and potentially downward pressure on the stock price due to perceived loss of institutional confidence.
Key Dates
| Date | Description |
|---|---|
| 2023-10-20 | Original Schedule 13D filing date. |
| 2023-12-26 | Date of the first amendment to the Schedule 13D. |
| 2024-10-24 | Date as of which 26,832,457 shares of common stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2024-10-31 | Date the Issuer's Quarterly Report on Form 10-Q was filed with the SEC. |
| 2024-11-18 | Date of event which required filing of this statement; Samsara LP sold 958,310 shares. |
| 2024-11-19 | Samsara LP sold 74,128 shares. |
| 2024-11-20 | Samsara LP sold 753,989 shares; Reporting Persons ceased to be beneficial owners of more than five percent of common stock. |
| 2024-12-30 | Dr. Akkaraju sold 9,333 shares. |
| 2025-03-27 | Date of signing and filing of this Amendment No. 2 to Schedule 13D. |
Recommendation
holdKeywords
Syros Pharmaceuticals, Samsara BioCapital, Schedule 13D/A, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Share Sales, SRNE
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.